Spyre Therapeutics Inc. (NASDAQ: SYRE) completed its underwritten public offering of 7,475,000 shares of common stock at $62.00 per share, according to a company statement.

The biotechnology company raised approximately $463.5 million in gross proceeds before deducting underwriting discounts, commissions and other offering expenses. The total share count included the full exercise of underwriters' option to purchase an additional 975,000 shares.

Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities LLC served as joint book-running managers for the offering. LifeSci Capital LLC acted as passive bookrunner.

The offering was conducted through a registration statement on Form S-3 that became effective February 27, 2026, with the Securities and Exchange Commission. A final prospectus supplement dated April 14, 2026 was filed with the SEC on April 16, 2026.

Spyre develops extended half-life antibodies targeting α4β7, TL1A, and IL-23 for inflammatory bowel disease and rheumatic diseases. The company is in clinical-stage development of these treatments.